XML 94 R57.htm IDEA: XBRL DOCUMENT
v3.21.2

Business combinations and investments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  |  |  |  |  |  |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 02, 2021 | Jun. 08, 2021 | Mar. 30, 2021 | Nov. 30, 2020 | Oct. 05, 2020 | Jul. 15, 2020 | Mar. 27, 2020 | Jan. 22, 2020 | Aug. 23, 2019 | Jan. 30, 2018 | Jul. 03, 2021 | Jun. 27, 2020 | Jul. 03, 2021 | Jul. 03, 2021 | Jun. 27, 2020 | Dec. 31, 2020 | Dec. 31, 2019 | Jun. 24, 2021 | Jan. 31, 2020
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected future amortization, remainder of fiscal year |  |  | $ 2,238 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected future amortization, year one |  |  | 4,475 |  |  |  |  |  |  |  |  |  |  |  |  | $ 28,262 |  |  |
Expected future amortization, year two |  |  | 4,381 |  |  |  |  |  |  |  |  |  |  |  |  | 23,910 |  |  |
Expected future amortization, year three |  |  | 4,350 |  |  |  |  |  |  |  |  |  |  |  |  | 22,297 |  |  |
Expected future amortization, year four |  |  | $ 4,350 |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,297 |  |  |
Acquisition costs |  |  |  |  |  |  |  |  |  |  | $ 1,833 |  | $ 5,029 |  |  |  |  |  |
Revenue of acquiree since acquisition date |  |  |  |  |  |  |  |  |  |  | 11,870 |  | 3,529 |  |  |  |  |  |
Acquisition integration costs and inventory related adjustments |  |  |  |  |  |  |  |  |  |  | 3,939 |  | $ 7,135 |  |  |  |  |  |
Variable interest entity, ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  | 8.80% |  |  |  |  |  |
Impairment of variable interest entity assets |  |  |  |  |  |  |  |  |  |  | 5,674 | $ 0 |  | $ 5,674 | $ 0 |  |  |  |
Impairment of variable interest entity assets, attributable to noncontrolling interest |  | $ 5,176 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of variable interest entity |  | $ 1,369 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investments |  |  |  |  |  |  |  |  |  |  | $ 17,737 |  | $ 17,737 | $ 17,737 |  |  |  |  |
Equity method investment, ownership percentage |  |  |  |  |  |  |  |  |  |  | 10.03% |  | 10.03% | 10.03% |  |  |  |  |
Income (loss) from equity method investments |  |  |  |  |  |  |  |  |  |  | $ 432 |  | $ 901 |  |  |  |  |  |
Period after receipt of statistical report for which the company may terminate agreement | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment due upon termination of agreement | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow deposit | 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred upon achievement of certain sales milestones | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration payable upon closing | $ 314,895 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Variable interest entity, ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  | 8.80% |  |  |  |  |  |
Debt instrument interest rate percentage |  |  |  |  |  |  |  |  |  |  | 2.60% |  | 2.60% | 2.60% |  |  |  |  |
Equity method investment ownership percentage |  |  |  |  |  |  |  |  |  |  | 10.03% |  | 10.03% | 10.03% |  |  |  |  |
Equity method investment |  |  |  |  |  |  |  |  |  |  | $ 17,737 |  | $ 17,737 | $ 17,737 |  |  |  |  |
Net losses from equity method investment |  |  |  |  |  |  |  |  |  |  | $ 432 |  | $ 901 |  |  |  |  |  |
Vaporox |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment owned, balance, shares (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 406,504 |
Investment owned, ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.00% |
Investment owned, cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |
Bioness, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of business acquired |  |  | 100.00% |  |  |  |  |  |  |  | 100.00% |  | 100.00% | 100.00% |  |  |  |  |
Contingent consideration at fair value |  |  | $ 43,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow deposit |  |  | 4,207 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration payable upon closing |  |  | 91,933 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration at fair value |  |  | 65,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | Convertible Debt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repayments of convertible debt |  |  | 1,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | Obtaining FDA Approval Of Certain Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration at fair value |  |  | 15,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment One |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration at fair value |  |  | 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | Meeting Net Sales Targets Over A Three-Year Period, Payment Two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration at fair value |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bioness, Inc | For Obtaining CMS Coverage And Reimbursement For Certain Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration at fair value |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CartiHeal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of business acquired |  |  |  |  |  |  |  |  |  |  | 100.00% |  | 100.00% | 100.00% |  |  |  |  |
Period after FDA approval for which company may exercise option to purchase remaining equity |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |  |
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |  |
Period after FDA approval for which company may exercise option to purchase remaining equity |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |  |
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |  |
CartiHeal | Series G Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares to be purchased upon completion of study (in shares) |  |  |  |  |  |  |  |  |  |  | 338,089 |  | 338,089 | 338,089 |  |  |  |  |
Additional investment to be purchased upon completion of study |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  | $ 5,000 | $ 5,000 |  |  |  |  |
Additional shares to be purchased upon completion of study (in shares) |  |  |  |  |  |  |  |  |  |  | 338,089 |  | 338,089 | 338,089 |  |  |  |  |
Additional investment to be purchased upon completion of study |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  | $ 5,000 | $ 5,000 |  |  |  |  |
Bio Ventus LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate, percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.50% |  |  |
Bio Ventus LLC | In Process Research and Development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets fair value disclosure |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,445 |  |  |
Bio Ventus LLC | Promissory Note | Harbor Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion converted instrument warrants issued |  |  |  |  |  |  | 428,572 |  |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | Harbor Medtech Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 91.20% |  |  |
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion converted instrument amount |  |  |  |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |
Debt instrument convertible conversion exercisable price |  |  |  |  |  |  | $ 1.167 |  |  |  |  |  |  |  |  |  |  |  |
Maturity date |  |  |  |  |  |  | Mar. 27, 2025 |  |  |  |  |  |  |  |  | Aug. 31, 2021 | Aug. 31, 2020 |  |
Debt instrument face amount |  |  |  | $ 320 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Refinanced with additional borrowings amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,811 |  |  |
Debt instrument interest rate percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8.00% |  |  |
Debt instrument frequency of periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | monthly |  |  |
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Promissory Note | Other Current Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt instrument face amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,845 |  |
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued during period shares new issues |  |  |  |  | 285,714 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued during period value new issues |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Series C Preferred Stock | Promissory Note |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt conversion converted instrument shares issued |  |  |  | 92,500 |  |  | 142,858 |  |  |  |  |  |  |  |  |  |  |  |
Debt instrument convertible conversion price |  |  |  | $ 3.50 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | Variable Interest Entity, Primary Beneficiary | Harbor Medtech Inc | Series C Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Variable interest entity, ownership percentage |  |  |  |  |  |  |  |  | 3.10% |  |  |  |  |  |  |  |  |  |
Variable interest entity shares purchased |  |  |  |  |  |  |  |  | 285,714 |  |  |  |  |  |  |  |  |  |
Variable interest entity, ownership percentage |  |  |  |  |  |  |  |  | 3.10% |  |  |  |  |  |  |  |  |  |
Variable interest entity cost |  |  |  |  |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | CartiHeal Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investments |  |  |  |  |  | $ 16,579 |  |  |  |  |  |  |  |  |  | $ 18,689 |  |  |
Equity method investment, ownership percentage |  |  |  |  |  |  |  |  |  | 2.80% |  |  |  |  |  |  |  |  |
Income (loss) from equity method investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (467) |  |  |
Period after FDA approval for which company may exercise option to purchase remaining equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |
Equity method investment ownership percentage |  |  |  |  |  |  |  |  |  | 2.80% |  |  |  |  |  |  |  |  |
Equity method investment aggregate cost |  |  |  |  |  |  |  |  |  | $ 2,500 |  |  |  |  |  |  |  |  |
Equity method investment capitalized transaction costs |  |  |  |  |  | 1,427 |  |  |  |  |  |  |  |  |  |  |  |  | $ 152
Equity method investment |  |  |  |  |  | $ 16,579 |  |  |  |  |  |  |  |  |  | $ 18,689 |  |  |
Net losses from equity method investment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (467) |  |  |
Period after FDA approval for which company may exercise option to purchase remaining equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |
Period after FDA approval for which CartiHeal may exercise option that requires the Company to purchase the remaining equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45 days |  |  |
Bio Ventus LLC | CartiHeal Ltd | Option and Equity Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in equity ownership percentage |  |  |  |  |  | 10.03% |  |  |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | CartiHeal Ltd | Simple Agreement For Future Equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional investment,cash paid |  |  |  |  |  |  |  | $ 152 |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares to be purchased upon completion of study (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 338,089 |  |  |
Additional investment to be purchased upon completion of study |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |
Additional shares to be purchased upon completion of study (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 338,089 |  |  |
Additional investment to be purchased upon completion of study |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |
Bio Ventus LLC | CartiHeal Ltd | Series G Preferred Stock | Option and Equity Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares purchased |  |  |  |  |  | 1,014,267 |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares purchased Value |  |  |  |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Bio Ventus LLC | CartiHeal Ltd | Series F Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued |  |  |  |  |  |  |  |  |  | 337,397 |  |  |  |  |  |  |  |  |
Bio Ventus LLC | CartiHeal Ltd | Series G1 Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued |  |  |  |  |  | 12,825 |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Asset impairment charges, attributable to noncontrolling interest. + References No definition available. + Details
Name: | bvs_AssetImpairmentChargesAttributableToNoncontrollingInterest
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business acquisition, payment due upon termination of agreement. + References No definition available. + Details
Name: | bvs_BusinessAcquisitionPaymentDueUponTerminationOfAgreement
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business acquisition, period of notice for termination. + References No definition available. + Details
Name: | bvs_BusinessAcquisitionPeriodOfNoticeForTermination
Namespace Prefix: | bvs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business combination, consideration transferred upon achievement of certain sales milestones. + References No definition available. + Details
Name: | bvs_BusinessCombinationConsiderationTransferredUponAchievementOfCertainSalesMilestones
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Debt instrument convertible conversion exercisable price. + References No definition available. + Details
Name: | bvs_DebtInstrumentConvertibleConversionExercisablePrice
Namespace Prefix: | bvs_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Debt instrument refinanced with additional borrowings amount. + References No definition available. + Details
Name: | bvs_DebtInstrumentRefinancedWithAdditionalBorrowingsAmount
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity method investment additional investment purchased shares. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentAdditionalInvestmentPurchasedShares
Namespace Prefix: | bvs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity method investment, additional investment to be purchased upon completion of study, amount. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyAmount
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity method investment, additional investment to be purchased upon completion of study, shares. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedUponCompletionOfStudyShares
Namespace Prefix: | bvs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity method investment additional investment to be purchased value. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentAdditionalInvestmentToBePurchasedValue
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity method investment capitalized transaction costs. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentCapitalizedTransactionCosts
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity method investment, period after FDA approval for investee to exercise option for remaining equity to be purchased. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvesteeToExerciseOptionForRemainingEquityToBePurchased
Namespace Prefix: | bvs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity method investment, period after FDA approval for investor to purchase remaining investment. + References No definition available. + Details
Name: | bvs_EquityMethodInvestmentPeriodAfterFDAApprovalForInvestorToPurchaseRemainingInvestment
Namespace Prefix: | bvs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of intangible assets used to determined using the income approach through excess earnings analysis with projected earnings discounted rate,percentage. + References No definition available. + Details
Name: | bvs_FairValueOfIntangibleAssetsUsedToDeterminedUsingTheIncomeApproachThroughExcessEarningsAnalysisWithProjectedEarningsDiscountedRatepercentage
Namespace Prefix: | bvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Investment owned, ownership percentage. + References No definition available. + Details
Name: | bvs_InvestmentOwnedOwnershipPercentage
Namespace Prefix: | bvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Variable interest entity, impairment. + References No definition available. + Details
Name: | bvs_VariableInterestEntityImpairment
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Variable interest entity issued cost. + References No definition available. + Details
Name: | bvs_VariableInterestEntityIssuedCost
Namespace Prefix: | bvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Variable interest entity shares issued during period. + References No definition available. + Details
Name: | bvs_VariableInterestEntitySharesIssuedDuringPeriod
Namespace Prefix: | bvs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationIntegrationRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The price per share of the conversion feature embedded in the debt instrument. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 + Details
Name: | us-gaap_DebtInstrumentConvertibleConversionPrice1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69C -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 55 -Paragraph 69B -URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the frequency of periodic payments (monthly, quarterly, annual). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823 + Details
Name: | us-gaap_DebtInstrumentFrequencyOfPeriodicPayment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 440 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629 + Details
Name: | us-gaap_EscrowDeposit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cost of the investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 + Details
Name: | us-gaap_InvestmentOwnedAtCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585 + Details
Name: | us-gaap_RepaymentsOfConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions. + References No definition available. + Details
Name: | us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions. + References No definition available. + Details
Name: | us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685 + Details
Name: | us-gaap_VariableInterestEntityOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_VaporoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bvs_BionessIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bvs_ObtainingFDAApprovalOfCertainProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bvs_MeetingNetSalesTargetsOverAThreeYearPeriodPaymentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=bvs_ForObtainingCMSCoverageAndReimbursementForCertainProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=bvs_CartiHealMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bvs_BioVentusLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=bvs_PromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=bvs_HarborCommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bvs_HarborMedtechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=bvs_HarborSeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bvs_CartiHealLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bvs_AgreementAxis=bvs_OptionAndEquityPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bvs_AgreementForFutureEquityAxis=bvs_SimpleAgreementForFutureEquityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=bvs_SeriesFConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=bvs_SeriesG1PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |